ArticleScientific reports2025
Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunosenescence and Cancer: Cellular Aging Programs That Reshape Antitumor Immunity.Immune network · 2026Review
- SARS-CoV-2 Anti-Spike IgG Subclass Titres in a Population with Prior Exposure to Perfluorooctanoic Acid (PFOA).Toxics · 2026Article
- LatentBiomolecules · 2025Article
- Influence of circadian rhythm on the determination of the IMMune Age indeX (IMMAX).Frontiers in aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immune response to infection or vaccination is compromised with age. We aimed to examine associations between immune senescence, T and B cell clonal diversity and immunoglobulin G secretion in response to immune challenge in isolated peripheral blood mononuclear cells (PBMC) from people of different chronological ages. We isolated PBMC from 49 individuals categorised into < 35 years and > 60 years age groups. Cells were then challenged with recombinant SARS-CoV-2 spike protein or vehicle and IMMAX score was calculated for each sample from flow cytometry. Antibody response was assessed using the proxy of IgG secretion and T cell receptor and immunoglobulin framework region recombination was determined by clonality studies. We observed that individuals aged > 60 years demonstrated a higher immune 'age' as calculated by IMMAX score (0.75 compared with 0.48 for individuals aged < 35 years; p = < 0.0001). Immune age negatively correlated with IgG responsivity in older individuals with recent prior exposure to SARS-CoV-2 (b = -0.01; p = 0.05). Higher immune age was also negatively correlated with TCR Vd + Jd receptor diversity regardless of immune challenge (b = -0.02; p = < 0.0001 and b = -0.02; r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.